|
|
 |
|
Viewing report
|
|
|
|
The North America Biotechnology Sectors : A Company and Industry Analysis (September 2004)
Mergent, Sep 2004, Pages: 32
This report looks at the biotechnology sectors in the United States and Canada, including the research, development and manufacturing and marketing and distribution segments
Current Environment - Key Points
- The strong rebound in the global biotech industry continued into the first half of 2004, driven largely by product successes
Publicly traded biotech companies registered an improvement of 65% in their net losses while increasing their employment by 9% during the year
- In the US, the increase in new product approvals and promising results in clinical trials of experimental drugs have accelerated the recovery of the biotech sector
- Pharmaceutical companies in the US are increasingly carrying out mergers and acquisitions with biotech companies to fill their pipelines with new drugs and replicate their initial successful earnings
- The Canadian biotech sector experienced a strong rebound in 2003, with revenues of public biotech companies climbing 18% to US$1.73 million
- While the Canadian biotech sector is fundamentally strong, its continued financial health faces significant challenges
Cash positions of public biotech companies continued to deteriorate and net loss of the sector surged 123% to US$586 million in 2003
Industry Profile - Key Points
- As of mid March 2004, the market capitalization of publicly traded biotech companies in the US was $311 billion, up nearly 51% from $206 billion recorded in 2003
- Venture capital investment in the US biotech sector has remained robust over the last few years
Investments in the biotech sector accounted for more than 20% of all venture capital investments in the US in the first quarter of 2004
- Employment in the biotech sector grew 6.3% in 2003 after increasing by 12% in the 2000 to 2002 period, representing the fastest growth for any major industry in the US
- The Canadian biotech industry ranks second only to the US in the number of biotech companies, and generates revenues that rank third globally, behind the US and the UK
- The number of biotech companies grew 12.7% from the previous year to 470 companies in 2003, with about 17% of them being publicly traded
Market Trends and Outlook - Key Points
- The increase in the world's population and the need to increase food production to meet rising demand has given rise to the rapid adoption of biotech by farmers around the world
- Ageing populations in many countries has driven the increase in global health care expenditure, expanding market opportunities enormously for biotech drugs and treatments
- As biotech food products become part of agricultural international trade, consumers- opinions on safety and necessity of biotech food products have become a dominant force behind changing agricultural trade policies
- The outlook for the US biotech sector should remain positive throughout 2004, buoyed by the recovery of the US economy and improvements in the capital markets
- As the patents of many biotech drugs expire in the next several years, generic drugmakers will jump into the market with therapeutic equivalents
- The growing complexity, demand and cost of new generations of drugs is expected to continue to accelerate the development of plant-generated biopharmaceuticals
Customers who bought this item also bought
Biotechnology - Global Outlook
Agricultural Biotechnology - Global Strategic Business Report
Biopharmaceuticals - A Global Market Overview
Biotechnology Instrumentation - Global Strategic Business Report
Nanobiotechnology - Global Strategic Business Report
Biotech 2010 Life Sciences: Adapting for Success
Biotech 2011-Life Sciences: Looking Back to See Ahead
Proteomics - Global Strategic Business Report
Success with Biobetters: Young Biobetters Companies and Pipelines
Bioinformatics - Global Strategic Business Report
|
|
|
|
